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BACKGROUND: The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive
non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or
undergoing autologous stem cell transplantation (SCT). In contrast, the role of PET before reduced-intensity condi-
tioning (RIC) and followed by allogeneic SCT has not been investigated to date. METHODS: PET was used to assess
80 patients who had chemosensitive disease (34 patients with HG-NHL and 46 patients with HL) before they under-
went allogeneic SCT: 42 patients had negative PET studies, and 38 patients had positive PET studies. Patients under-
went allograft from matched related siblings (n ¼ 41) or alternative donors (n ¼ 39). RESULTS: At the time of the last
follow-up, 48 patients were alive (60%), and 32 had died. The 3-year cumulative incidence of nonrecurrence mortality
and disease recurrence was 17% and 40%, respectively. The cumulative incidence of disease recurrence was signifi-
cantly lower in the PET-negative patients (25% vs 56%; P ¼ .007), but there was no significant difference between
the patients with or without chronic graft-versus-host disease (P ¼ .400). The patients who had negative PET studies
before undergoing allogenic SCT also had significantly better outcomes in terms of 3-year overall survival (76% vs
33%; P ¼ .001) and 3-year progression-free survival (73% vs 31%; P ¼ .001). On multivariate analysis, overall survival
was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type of donor (HR, 6.26
for haploidentical vs sibling; HR, 1.94 for matched unrelated donor vs sibling). CONCLUSIONS: The current results
indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients who are eligible for
RIC allografting. Cancer 2010;116:5001–11. VC 2010 American Cancer Society.
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Patients with Hodgkin lymphoma (HL) or aggressive non-Hodgkin lymphoma (NHL) who develop disease recur-
rence after autologous stem cell transplantation (SCT) or who have refractory disease often are candidates for allogeneic
SCT (alloSCT). The use of reduced-intensity conditioning (RIC) regimens followed by alloSCT has been investigated
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mainly in such patients or those with comorbidities; how-
ever, although the majority of studies have reported a
reduction in nonrecurrence mortality (NRM), the risk of
disease recurrence remains considerable.
All of the published studies in patients with HL who
underwent RIC alloSCT reported 2-year progression-free
survival (PFS) rates of 30% to 40% with better long-term
outcomes in patients who had chemosensitive disease or
who developed chronic graft-versus-host disease
(GVHD).1-3 RIC regimens also have been investigated in
patients with aggressive lymphomas: Most of those studies
included various B-cell and T-cell histotypes, and the esti-
mated 3-year PFS rates have been 15% to 20% in patients
with chemoresistant disease and 45% to 55% in patients
with chemosensitive disease.4-7
Chemosensitivity is 1 of the most important prog-
nostic factors affecting final outcomes in patients who
receive myeloablative conditioning, and is also important
for patients who receive RIC regimens. We recently dem-
onstrated better overall survival (OS) and PFS in patients
with lymphoma who underwent an allograft in complete
remission compared with the survival of patients who
underwent transplantation in partial remission or with re-
fractory disease.8
Because RIC regimens involve less chemoradiother-
apy and rely more on the so-called graft-versus-tumor
effect that takes several months to occur, it is important to
know whether residual disease is present at the time of
alloSCT. Over the last 10 years, it has been established
that 18-fluoro-deoxyglucose (FDG)-positron emission to-
mography (FDG-PET) is useful in the pretreatment stag-
ing, therapeutic monitoring, and post-therapeutic
evaluation of patients with lymphoma. It is highly sensi-
tive and specific in HL and in the majority of aggressive
lymphoma subtypes, and it is noteworthy that the results
are predictive of outcome in patients with recurrent HL or
NHL who receive high-dose chemotherapy and undergo
autologous SCT.9-11 The objective of the current retro-
spective study was to assess the prognostic role of FDG-
PET in patients with chemosensitive HL or aggressive
NHL before RIC alloSCT.
MATERIALS AND METHODS
Patient Characteristics
BetweenMay 2001 and December 2007, 80 patients were
enrolled retrospectively in a study that involved depart-
ments of hematology from 4 Italian institutions; although
the period of enrolment was 6 years, the majority of
patients (63 of 80; 79%) received allografts between 2004
and 2007. The patients were selected from the database of
each department of hematology if they meet the following
criteria: 1) patients with recurrent HL or aggressive NHL
who had a clinical response (complete or partial remis-
sion) to salvage therapy; 2) patients who were eligible for
RIC alloSCT from related or alternative donors; 3)
patients who had FDG-PET studies obtained in addition
to contrast-enhanced computed tomography (CT) studies
no more than 60 days before starting the RIC regimen.
The median time interval between the last salvage therapy
and FDG-PET was 30 days (range, 6-60 days).
Approval was obtained from the institutional review
boards of the participating centers, and all patients pro-
vided written informed consent. Tables 1 and 2 summa-
rizes the patient characteristics. The median age patient
was 36 years (range, 17-65 years). Forty-six patients had
HL, and 34 patients had NHL, including 22 with diffuse
large B-cell lymphoma (DLBCL) and 12 with T-cell NHL
(T-NHL) (11 peripheral T-cell lymphomas and 1 lym-
phoblastic T cell lymphoma). Sixty-four patients (80%)
had failed a previous autologous SCT (42 patients with
HL and 22 patients with NHL). The population included
12 patients with primary refractory disease who underwent
a tandem autologous SCT and alloSCT. Only a few
patients had bulky disease before salvage therapy (10%).
Salvage Therapy and Conditioning Regimens
Different salvage therapies were used and are summarized
in the Table 1. Forty-three patients received grafts from
related siblings (41 from matched siblings and 2 from 1-
antigen mismatched, related siblings), 20 patients received
grafts from matched unrelated donors (MUDs), and 17
patients received grafts from haploidentical family donors.
Thirty patients (69%) who received allografts from related
siblings also received an RIC regimen containing thiotepa
(10 mg/kg), cyclophosphamide (60 mg/kg), and fludara-
bine (60 mg/m2)8; 8 patients received a combination of
fludarabine (90 mg/m2) and cyclophosphamide (900 mg/
m2); and 5 patients received a combination of treosulfan
(42 g/m2) and fludarabine (150 mg/m2). In case of related
siblings, GVHD prophylaxis consisted of cyclosporine A
adjusted to maintain blood levels of 200 to 300 ng/mL
and a short course of methotrexate (10 mg/m2 on Dayþ1
and 8mg/m2 onDaysþ3 andþ6).
Twelve patients who received allografts from MUD
donors also received a combination of thiotepa (10 mg/
kg) and cyclophosphamide (100 mg/kg); 3 patients
received a combination of fludarabine (150 mg/m2) and
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melphalan (140 mg/m2); and 5 patients received a combi-
nation of treosulfan and fludarabine. The grafts were
depleted of T cells using rabbit antithymocyte globulin
(thymoglobulin 3.5 mg/kg daily on Days 4 and 3).
Post-transplantation GVHD prophylaxis consisted of cy-
closporine A and a short course of methotrexate (10 mg/
m2 on Dayþ1 and 8 mg/m2 on Daysþ3 andþ6).
All 17 patients who received allografts from haploi-
dentical donors received conditioning with thiotepa (10
mg/kg), cyclophosphamide (60 mg/kg), and fludarabine
(120 mg/m2) along with total-body irradiation (2 grays);
CD34-positive cell selection and alemtuzumab treatment
(15 mg/m2 on Day 2) were used for ex vivo and in vivo
T-cell depletion.12 Those patients did not receive any
GVHD prophylaxis. Acute GVHD was defined on the
basis of the criteria published by Glucksberg et al, and
Table 1. Patient Characteristics
No. of
Patients (%)
Characteristic HL, n 5 46 Aggressive
NHL, n 5 34
Median age at AlloSCT [range], y 30 [17-55] 48 [17-61]
Median time from diagnosis to
AlloSCT [range], mo
41 [11-170] 19 [5-87]
No. of previous therapy lines
£2 17 (37) 19 (56)
>2 29 (63) 15 (44)
Previous AutoSCT 42 (91) 22 (65)
Time to AutoSCT-AlloSCT, moa
£12 20 (47) 14 (64)
>12 22 (53) 8 (36)
Donor type
HLA-matched sibling 27 (58) 16 (47)
MUD 7 (16) 13 (38)
Haploidentical 12 (26) 5 (15)
Salvage therapies before AlloSCT
Cisplatin-based:
Gem/cisplatin, DHAP
13 (28) 6 (18)
IGEV 6 (13) —
MOPP 4 (9) —
Anthracycline-based: CHOP/CNOP — 4 (12)
High-dose cytarabine 13 (28) 13 (38)
AutoSCT 7 (15) 5 (15)
Others therapies 3 (7) 6 (17)
HL indicates Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; AlloSCT,
allogeneic stem cell transplantation; AutoSCT, autologous stem cell trans-
plantation; HLA, human leukocyte antigen; MUD, matched unrelated donor;
Gem, gemcitabine; DHAP, dexamethasone, cisplatin, and cytarabine; IGEV,
ifosfamide, gemcitabine, vinorelbine, and prednisolone; MOPP, mechloret-
amine, vincristine, prednisone, and procarbazine; CHOP, cyclophospha-
mide, vincristine, doxorubicin, and prednisone; CNOP, cyclophosphamide,
mitoxantrone, vincristine, and prednisone.
a Data were available only for patients who underwent AutoSCT.
Table 2. Patient Characteristics According to
[18-F]Fluorodeoxyglucose-Positron Emission Tomography
No. of
Patients (%)
Variable FDG-PET
Negative,
n 5 42
FDG-PET
Positive,
n 5 38
Median age at AlloSCT [range], y 37 [17-59] 36 [17-65]
Karnofsky performance status
‡80% 36 (86) 26 (68)
<80% 6 (14) 12 (32)
Histology
HL 23 (55) 23 (61)
Aggressive NHLa 19 (45) 15 (40)
Time from diagnosis to AlloSCT, mo
£24 21 16
>24 21 22
Previous therapy lines
£2 22 13
>2 20 25
Previous AutoSCT 33 (79) 31 (82)
Extranodal disease
Yes 12 (29) 11 (29)
No 29 (69) 27 (71)
NA 1 (2) —
Bulky disease
Yes 3 (7) 5 (13)
No 38 (91) 33 (67)
NA 1 (2) —
CT results
CR 21 (50) 8 (21)
PR 17 (40) 27 (71)
NA 4 (10) 3 (8)
Time to AutoSCT-AlloSCT, mo
£12 17 (52) 17 (55)
>12 16 (48) 14 (45)
Donor sex
Male patient/female donor 8 (19) 10 (26)
Other combinations 34 (81) 28 (74)
Donor type
HLA-matched sibling 24 (57) 19 (50)
MUD 10 (24) 10 (26)
Haploidentical 8 (19) 9 (24)
FDG-PET indicates [18-F]fluorodeoxyglucose positron emission tomogra-
phy; AlloSCT, allogeneic stem cell transplantation; HL, Hodgkin lymphoma;
NHL, non-Hodgkin lymphoma; AutoSCT, autologous stem cell transplanta-
tion; NA, not available; CT, total body computed tomography; CR, complete
remission; PR, partial remission; HLA, human leukocyte antigen; MUD,
matched unrelated donor.
a In total, there were 13 patients with diffuse large B-cell lymphoma
(DLBCL) and 6 patients with T-cell NHL (T-NHL) in the FDG-PET–negative
group and 9 patients with DLBCL and 6 patients with T-NHL in the FDG-
PET–positive group (P ¼ 0.72). Aggressive NHL categorized according to
the International Prognostic Index was well balanced in the FDG-PET–neg-
ative and FDG-PET–positive groups (P ¼ .75).
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chronic GVHD was classified as limited or extensive on
the basis of the criteria of Sullivan et al.13,14
Staging Procedure and FDG-PET Imaging
Disease status before and after alloSCT was assessed by
means of a physical examination, blood chemistry, con-
trast-enhanced CT, bone marrow biopsy (when clinically
indicated), and FDG-PET imaging (FDG-PET/CT from
2004 onward). PET/CT is more sensitive and specific
than contrast-enhanced CT for the evaluation of lymph
node and extranodal lymphomatous involvement.
Clinical response was evaluated on the basis of the
criteria published by Cheson et al.15 These older criteria
were used because the patients received allografts before
December 2007, and new criteria were defined in 2007.
Whole-body FDG-PET imaging was performed
using a General Electric Discovery LS 2-dimensional
mode (GE Medical Systems, Waukesha, Wis) in 59
patients (74%), a Siemens Biograph Duo LSO 3-dimen-
sional mode in 11 patients, and a Siemens Eccat Accel 3-
dimensional mode in 10 patients (Siemens Healthcare,
Erlangen, Germany). After the patients had refrained
from eating or drinking for at least 6 hours, all 2-dimen-
sional (2D) or 3D FDG-PET scans were performed with
the injection of approximately 370 megabecquerels of 18-
fluorodeoxyglucose (18-FDG). After a 60-minutes uptake
period, a CT scout was acquired to define the body axial
extension to be imaged (from the pelvis to the base of the
skull); then, a helical CT scan was acquired during shal-
low breathing. At the end of the CT scan, the bed position
was translated into the FDG-PET field of view for the ac-
quisition of FDG-PET data of whole-body tracer distri-
bution, and the FDG-PET images were reconstructed
using an interative algorithm.
The images were reviewed by 3 experienced nuclear
medicine physicians who were blinded to the patients’
clinical, radiologic, and follow-up data. The PET scans
from each patient recorded before and after alloSCT were
obtained in the same department of nuclear medicine.
The FDG-PET scans were interpreted using the cri-
teria of Juweid et al.16 Briefly, a positive scan was defined
as visually analyzed focal or diffuse FDG uptake above the
background (mediastinal blood pool activity is recom-
mended as the reference background activity) in a location
incompatible with normal anatomy/physiology.16
Study Endpoints and Statistical Analysis
The objective of this study was to evaluate the role of
FDG-PET in predicting the risk of disease recurrence and
NRM, PFS, and OS. The OS and PFS curves were esti-
mated using the Kaplan-Meier method and were com-
pared using log-rank tests, and Cox regression models
were used for multivariate analyses. Crude cumulative
incidence curves of disease recurrence and NRM were
estimated in a competing risk framework17: When analyz-
ing NRM, disease recurrence was regarded as a competing
event, and vice versa. Univariate comparisons of the cu-
mulative incidence curves were made by means of the
Gray test,18 and Fine and Gray models were applied for
multivariate analyses.19 Age was modeled as a continuous
variable using 3-knot, restricted cubic splines.20
The effect of chronic GVHD on the cumulative
incidence of disease recurrence was investigated by using
the ‘‘semilandmark’’ analysis described by Baron et al21
with a landmark time of 5 months (the modal time of
chronic GVHD onset in our case series). Chronic GVHD
also was included as a time-dependent variable in a multi-
variate Cox analysis of its prognostic effect on OS, and the
model also included FDG-PET status and the type of do-
nor as covariates. A multivariate binary logistic model was
used to test the dishomogeneity between the FDG-PET-
negative and FDG-PET-positive groups in relation to
common characteristics, the effects of which were tested
in 2-sidedWald tests.
RESULTS
CT and FDG-PET Results
Before alloSCT, 42 patients had negative FDG-PET
results, and 38 patients had positive FDG-PET results.
The series included 12 patients with primary refractory
disease who received a tandem autologous and alloSCT
(including 8 patients with negative FDG-PET results,
and 4 patients with positive FDG-PET results). The 2
groups were well balanced in terms of pretransplantation
characteristics among the variables listed in Table 2.
CT results were statistically significant (P ¼ .008)
only in the multivariate logistic model. Moreover, the
number of patients with DLBCL and T-NHL and the
International Prognostic Index (IPI) for each were well
balanced between the 2 groups (FDG-PET-negative, 13
DLBCLs and 6 T-NHLs; FDG-PET-positive, 9 DLBCLs
and 6 T-NHLs; P ¼ .72), with IPI scores 2 for 13
FDG-PET-negative patients and for 11 FDG-PET-posi-
tive patients (P¼ .75).
Thirty-three patients and 31 patients underwent
previous autologous SCT in the FDG-PET-negative and
FDG-PET-positive groups, respectively. The number of
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patients who developed recurrent disease within 1 year of
autograft was not statistically significant.
Before the allograft, 21 of 42 FDG-PET-negative
patients (50%) were in complete remission (CR), and 17
of 42 patients (41%) were in partial remission (PR) as
assessed by contrast-enhanced CT. The corresponding
proportions among the 38 FDG-PET-positive patients
were 8 patients in CR (21%) and 27 patients in PR
(71%).
The CT results (CR vs PR) did not significantly
affect PFS (P ¼ .232) or OS (P ¼ .356). Because the CT
results (CR vs PR) were not significant in univariate anal-
ysis, this variable was not included in the multivariate
analysis.
Four PET-negative patients and 3 PET-positive
patients were identified as chemosensitive during salvage
therapy and, thus, did not have repeat CT studies at the
time of FDG-PET evaluation. Twenty-seven of 38 PET-
positive patients (71%) had multiple FDG uptake sites,
and 11 PET-positive patients had only 1 FDG uptake site.
Seven of those 11 patients developed disease recurrence af-
ter alloSCT; in only 1 of the remaining 4 patients, it is pos-
sible that the focal FDG uptake was a false-positive.
Of the 42 PET-negative patients, 32 patients (76%)
did not develop disease recurrence: Twenty-seven patients
remained alive and in CR after a median of 37 months of
follow-up (range, 6-89 months), and 5 patients (3 with
HL and 2 with NHL) died of other causes while in remis-
sion. The remaining 10 patients (24%) developed disease
recurrence a median of 6 months after alloSCT (4 patients
died of disease, and 6 patients remained alive). Twenty-
one of the 38 PET-positive patients (55%) developed dis-
ease recurrence: Fifteen of those patients died of progres-
sive disease, and 6 patients remained alive (all but 1 with
chronic GVHD). Of the 17 patients (44%) who did not
develop disease recurrence, 8 died of NRM a median of 3
months after alloSCT, and 9 remained alive (only 1
patient had a low performance status, 4 patients experi-
enced limited chronic GVHD, and all patients had a low
maximum standardized uptake value) (Fig. 1).
Lymphoma Recurrence
The disease recurred or progressed in 31 of 80 patients
and was the cause of death for 19 patients. At a median
follow-up of 37 months (interquartile range, 21-51
months), the 1-year and 3-year crude cumulative inci-
dence (CCI) of disease recurrence was37% (95% confi-
dence interval [CI], 28%-50%) and 40% (95%CI, 31%-
54%), respectively, indicating that disease recurred during
the first year after alloSCT.
Preallograft FDG-PET status significantly influ-
enced the 3-year CCI of disease recurrence, which was
25% in the PET-negative group and 56% in the PET-
positive group (P ¼ .007) (Fig. 2). There was a trend to-
ward a reduced risk of disease recurrence in the patients
who received allografts from alternative donors, with 3-
year CCIs of 19% (95%CI, 6%-57%) for those who had
haploidentical donors, 31% (95%CI, 15%-61%) for
those with MUDs, and 53% (95%CI, 40%-72%) for
those with matched related siblings (P¼ .050).
In a Fine and Gray multivariate model that included
preallograft FDG-PET status, performance status, patient
age, the type of lymphoma, the type of donor, the number
of previous therapies, failed autologous SCT, and the
time interval between diagnosis and alloSCT, only FDG-
PET status (P ¼ .008) and the type of donor (P ¼ .018)
significantly influenced the CCI of disease recurrence.
Separate analyses of the outcomes for patients with
NHL and patients with HL indicated that patients with
NHL who had positive pretransplantation FDG-PET
Figure 1. Patient outcomes according to functional imaging are illustrated. PET indicates positron emission tomography; PS:
performance status.
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scans were at increased risk of disease recurrence (3-year
CCI of disease recurrence, 53%; 95%CI, 32%-89%)
compared with those who had negative scans (3-year CCI
of disease recurrence, 23%; 95%CI, 9%-56%; P¼ .049).
The corresponding rates for patients with HL who had
positive FDG-PET scans were 59% (95%CI, 41%-86%)
and 27% (95%CI, 13%-55%; P¼ .066) (Fig. 2). In addi-
tion, the 3-year CCI of disease recurrence did not differ
significantly between patients with DLBCL and patients
with T-NHL (37% vs 35%, respectively; P¼ .99). When
the CT and FDG-PET results were combined, the 3-year
CCI of disease recurrence was 27% for CT/PET-negative
patients in CR, 43% for CT/PET-positive patients in CR,
26% for CT/PET-negative patients in PR, and 65% for
CT/PET-positive patients in PR (P¼ .033, Fig. 3).
OS, PFS, and NRM
The median follow-up for the population as a whole was
37 months (interquartile range, 21-51 months). At the last
follow-up, 48 patients remained alive (60%), and 32
patients had died. The 3-year OS and PFS estimates were
55% (range, 43%-66%) and 54% (range, 41%-65%),
respectively.: In the HL andNHL groups, the OS estimates
were 56% (38%-70%) and 52% (33%-67%), respectively;
and the PFS estimates were 51% (34%-65%) and 58%
(38%-73%), respectively. In addition, the subtype of
aggressive lymphoma did not significantly affect PFS or OS
(3-year PFS, 60% vs 57%; P ¼ .76; 3-year OS, 56% vs
47%; P¼ .34) for DLBCL and T-NHL, respectively.
Figure 2. The cumulative incidence of disease recurrence is
illustrated according to [18-F]fluorodeoxyglucose positron
emission tomography (PET) status before allogeneic stem
cell transplantation. (A) The crude cumulative incidence
(CCI) of disease recurrence is illustrated for all patients. (B)
The CCI of disease recurrence is illustrated for patients with
Hodgkin lymphoma. (C) The CCI of disease recurrence is
illustrated for patients with non-Hodgkin lymphoma.
Figure 3. The crude cumulative incidence (CCI) of disease re-
currence is illustrated according to [18-F]fluorodeoxyglucose
positron emission tomography (PET) status and the results
from contrast-enhanced total body computed tomography
(CT). CT-CR indicates complete remission as assessed by
means of contrast-enhanced total body CT; CT-PR, partial
remission as assessed by means of contrast-enhanced total
body CT.
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The PET-negative patients had significantly better
outcomes, including a 3-year OS rate of 76% versus 33%
for PET-positive patients (P < .001) and a 3-year PFS
rate of 73% versus 31% for PET-positive patients (P <
.001) (Fig. 4). The corresponding rates were 82% (58%-
93%) versus 28% (8%-52%; P ¼ .006) and 72% (47%-
86%) versus 30% (11%-52%; P¼ .027) in the HL group,
and 69% (40%-86%) versus 33% (12%-56%; P ¼ .022)
and 76% (48%-91%) versus 34% (11%-60%; P ¼ .009)
in the NHL group.
In the multivariate Cox model for OS, a positive
FDG-PET scan before alloSCT and a poor performance
status were independent adverse prognostic factors with a
hazard ratio (HR) of 3.35 (95%CI, 1.49-7.52; P ¼ .003)
and 5.15 (95%CI, 2.19-12.11; P ¼ .0002), respectively
(Table 3). In addition, significantly shorter survival was
associated with the use of an MUD (HR, 1.94; 95%CI,
0.78-4.83) or a haploidentical donor (HR, 6.26; 95%CI,
2.03-19.27; P ¼ .0048). The other prognostic factors did
not significantly affect outcomes. In the subgroup of
patients who had failed a previous autograft, the time
since autograft (<12 months or >12 months) did not
affect OS in the multivariate analysis.
A positive FDG-PET scan before alloSCT and a
poor performance status also were associated with inferior
PFS in a multivariate Cox model (positive FDG-PET:
HR, 3.03; (95%CI, 1.59-5.76; P¼ .0007; poor perform-
ance status: HR, 2.38; 95%CI, 1.16-4.89; P ¼ .0187).
However, the type of donor had no impact on PFS.
In an analysis that was restricted to 68 patients by
excluding those who underwent tandem autologous-
alloSCT, the same variables were associated with a worse
PFS (positive FDG-PET: HR, 2.56; 95%CI, 1.26-5.21;
P ¼ .0096; poor performance status: HR, 3.15; 95%CI,
1.36-7.29; P ¼ .0074) and OS (positive FDG-PET: HR,
2.61; 95%CI, 1.10-6.21; P ¼ .0296; poor performance
status: HR, 5.87; 95%CI, 2.27-15.17; P ¼ .0003)
whereas the type of donor affected only OS (P¼ .013).
In total, 13 patients died of NRM between 1 month
and 12.5 months after alloSCT, including 7 patients who
received grafts from haploidentical donors, 5 patients who
received grafts from MUD donors, and only 1 patient
who received a graft from a matched related sibling. The
causes of NRM were GVHD (n ¼ 2), thrombotic micro-
angiopathy (n¼ 1), and infections (n¼ 10).
The 1-year and 3-year CCIs of NRM were 15%
(95%CI, 9%-26%) and 17% (95%CI, 10%-28%). In
univariate analysis, transplantation from a haploidentical
donor or an MUD was associated with a higher rate of
NRM than transplantation from a matched related sib-
ling, with 3-year CCIs of 36% (95%CI, 18%-71%) and
31% (95%CI, 16%-63%) versus 2.5% (95%CI, 0.3%-
18%), respectively (P¼ .001). In the Fine and Gray mul-
tivariate model, the factors that significantly influenced
NRMwere type of donor (P< .001), previous autologous
SCT (P ¼ .047), and time from diagnosis to alloSCT (P
¼ .018). Performance status did not significantly affect
NRM (P¼ .080).
GVHD and Chimerism
Of the 78 evaluable patients (2 died early after alloSCT),
22 patients (28%) developed acute GVHD, including 12
who received allografts from matched siblings and 10 who
received allografts from alternative donors. Chronic
Figure 4. These Kaplan-Meier curves illustrate (A) progres-
sion-free survival (PFS) and (B) overall survival (OS) according
to [18-F]fluorodeoxyglucose positron emission tomography
PET) status.
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GVHDwas observed in 29 of 72 evaluable patients (40%),
including 16 patients with limited GVHD and 13 patients
with extensive GVHD (18 who received allografts from
matched siblings and 11 who received allografts from alter-
native donors).A semilandmark analysis indicated that the
3-year CCI for disease recurrence was 12% (95%CI, 3%-
47%) for patients with chronic GVHD and 21% (95%CI,
9%-48%) for patients without chronic GVHD (P¼ .400).
In the Cox model analysis of OS, chronic GVHD was not
statistically significant: The HR of the absence versus the
presence of chronic GVHD as a time-dependent variable
was 0.83 (95%CI, 0.30-1.35; P¼ .710).
Chimerism analyses were available in 60 patients
(75%), including 56 patients with fully donor chimerism
(93%) and 4 patients with mixed donor-recipient chimer-
ism (7%) within the first 6 months after alloSCT. Two of
4 patients with mixed chimerism developed disease recur-
rence after alloSCT. In 9 patients who died early after
alloSCT, chimerism analysis was not performed; whereas,
in 11 other patients, the results were not available.
DISCUSSION
To our knowledge, this is the first study demonstrating
that disease assessment by FDG-PET imaging before
alloSCT can predict long-term survival in patients who
develop disease recurrence and in patients with chemosen-
sitive HL or aggressive NHL. The patients in this study
who had negative PET results were at lower risk of disease
recurrence and had better PFS and OS than the PET-posi-
tive patients. It is noteworthy that the predictive value of
PET was independent of GVHD and of the graft-versus-
lymphoma effect.
Response assessment in patients with lymphomas
includes both conventional and metabolic imaging,
because the size of a residual mass correlates poorly with
Table 3. Multivariate Analyses of Overall and Progression-Free Survival by Cox Regression Model
OS PFS
Variable HR 95% CI Pa HR 95% CI Pa
FDG-PET status
Negative 1 — 1 —
Positive 3.35 1.49-7.52 .0035 3.03 1.59-5.76 .0007
Performance status
ECOG 0-1 1 — 1 —
ECOG ‡2 5.15 219-12.11 .0002 2.38 1.16-4.89 .0187
Age at AlloSCT, y
28 1 — 1 —
47 1.86 0.81-4.24 .265 0.97 0.49-1.89 .73
Histology
HL 1 — 1 —
Aggressive NHL 1.68 0.58-4.92 .341 1.77 0.73-4.33 .209
Time from diagnosis to AlloSCT, mo
£24 1 — 1 —
>24 2.20 0.71-6.80 .172 1.90 0.75-4.82 .178
No. of previous therapy lines
>2 1 — 1 —
£2 1 0.37-2.71 .994 1.14 0.50-2.55 .759
Previous AutoSCT
No 1 — 1 —
Yes 1.09 0.36-3.27 .883 1.29 0.48-3.46 .609
Type of donor
HLA-matched sibling 1 — 1 —
MUD 1.94 0.78-4.83 1.01 0.47-2.15
Haploidentical 6.26 2.03-19.27 .0048 1.29 0.50-3.29 .867
OS indicates overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; FDG-PET, [18-F]
fluorodeoxyglucose-positron emission tomography; ECOG, Eastern Cooperative Oncology Group; AlloSCT, allogeneic
stem cell transplantation; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; AutoSCT, autologous stem cell trans-
plantation; HLA, human leukocyte antigen; MUD, matched unrelated donor.
aWald test.
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prognosis, which is why revised response criteria for lym-
phoma using FDG-PET recently were published. Many
studies have confirmed that midtreatment FDG-PET
images can predict clinical outcome in patients with HL
or aggressive NHL,22,23 and an association between a neg-
ative pretransplantation PET scan and a better outcome
has was reported previously in the setting of high-dose
therapy and autologous SCT with 2-year event-free sur-
vival rates ranging from 60% to 80%.9,10
Patients with recurrent or progressive HL or aggres-
sive NHL after autologous transplantation have no poten-
tially curative treatment options other than alloSCT, and
identifying the risk factors that influence the outcome of
allografting would help to target optimal conditioning
and immunologically based post-transplantatoin thera-
pies for individual patients. Currently, the most widely
used prognostic factors are chemosensitive disease, comor-
bidity score, and donor type. Chemosensitive disease
before alloSCT has been identified as a strong prognostic
factor in patients who receive myeloablative conditioning,
but it may be even more relevant in patients who receive
RIC regimens.
Today, FDG-PET is used frequently to monitor
treatment response, but we believe the current investiga-
tion represents the first time FDG-PET has been used to
evaluate a large group of patients before alloSCT,
although 1 previous small study did consider the signifi-
cance of pretransplantation FDG-PET in 14 patients who
underwent conventional myeloablative alloSCT (includ-
ing only 1 patient with HL and no patients with
DLBCL).24 Several groups have described the results
from alloSCT after RIC in patients with recurrent and re-
fractory HL; and, although the published studies are het-
erogeneous in terms of RIC protocols and the duration of
follow-up, they indicate that disease status at the time of
alloSCT influenced outcome in all series and that out-
comes were favorable when patients developed recur-
rences >12 months after autologous SCT.25 Peggs et al
used an RIC regimen of fludarabine/melphalan and alem-
tuzumab and recorded a 4-year PFS rate of 67% and an
OS rate of 100% in patients who were in CR or uncertain
CR (CRu) at the time of transplantation.3 Furthermore,
Anderlini et al recently reported a 2-year PFS rate of 57%
in patients who achieved CR/CRu before alloSCT using a
similar RIC regimen without alemtuzumab.2 However,
none of those reports described a correlation between
FDG-PET findings and outcome.
Disease status also is critical to the outcome of
patients with aggressive NHL, and Dhedin et al reported
a 5-year OS rate of 76% in patients who achieved CR
before myeloablative alloSCT.26 Although there are rela-
tively few published studies of the outcome of RIC in
patients with aggressive NHL, it has been reported that
transplantation during CR can lead to a PFS rate of 50%
to 60%. Moreover, in our previous study, we did not
observe a significant difference in outcome between
patients with aggressive lymphoma of B-cell or T-cell ori-
gin, respectively, at 3 years of follow-up.8 This observa-
tion was confirmed in the current study.
The results from this study indicate that a negative
pretransplantation PET scan significantly predicts the risk
of disease recurrence, PFS, and OS in both patients with
HL and patients with NHL. These findings also were in
the analysis that was restricted to 68 patients (excluding
those who underwent tandem autologous-alloSCT).
It is noteworthy that, in our multivariate analysis,
performance status also was associated significantly with
PFS and OS. Previous reports demonstrated that hemato-
poietic cell transplantation-specific comorbidity index
(HCT-CI) and performance status were correlated inde-
pendently with outcome.27,28 Recently, Robinson et al
investigated a population of 285 patients with affected
HL who underwent RIC alloSCT and observed that both
performance status and disease status at transplantation
important clinical parameters for outcome.29
The kinetics of disease recurrence were quite differ-
ent in PET-positive patients: In patients with HL, disease
progression usually was observed within the first 2 years
after alloSCT; whereas most patients with aggressive
NHL developed disease recurrence within the first 12
months, and then the curve reached a plateau. Although
patients with positive pretransplantation PET scans had a
dismal outcome, approximately 30% of them survived for
a long period.
The main limitations of our study are related to the
potential drawbacks and selection biases associated with
retrospective analyses. We only considered patients who
underwent PET before alloSCT; thus, the population was
selected. Furthermore, because we included patients who
received allografts from different donor types, multivari-
ate analyses indicated that the type of donor influenced
OS and the risk of disease recurrence.
However, with regard to the other factors that may
influence outcome, the population was relatively homoge-
neous in terms of conditioning regimens, and we did not
include patients who received nonmyeloablative condi-
tioning regimens, such as 2 grays of total body irradiation
and fludarabine, which reportedly are associated with a
PET and Allogeneic Transplantation/Dodero et al
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higher risk of disease recurrence.30 In addition, most of
our patients (n ¼ 59; 74%) received conditioning regi-
mens that contained thiotepa, cyclophosphamide, and
fludarabine or thiotepa and cyclophosphamide. Further-
more, the majority (79%) received allografts between
2004 and 2007, and it is unlikely that there was any sub-
stantial change in supportive care strategies over such a
short time.
In conclusion, and despite its limitations, the results
from our retrospective study indicate that FDG-PET
imaging is useful in predicting PFS and OS after RIC
alloSCT. This represents a critical issue in the era of new
drugs, because patients who have positive scans should
receive further treatment to possibly increase the response
rate before alloSCT.
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